KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Capital Employed (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Return on Capital Employed for 12 consecutive years, with 0.09% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 27.0% to 0.09% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.09% through Dec 2025, up 27.0% year-over-year, with the annual reading at 0.08% for FY2025, 25.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.09% at Xenon Pharmaceuticals, up from 0.57% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.07% in Q1 2021, with the low at 0.57% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 0.25%, with a median of 0.23% recorded in 2023.
  • Peak annual rise in Return on Capital Employed hit 27bps in 2025, while the deepest fall reached -26bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 0.2% in 2021, then rose by 11bps to 0.17% in 2022, then tumbled by -56bps to 0.27% in 2023, then tumbled by -32bps to 0.36% in 2024, then surged by 75bps to 0.09% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.09%, 0.57%, and 0.47% for Q4 2025, Q3 2025, and Q2 2025 respectively.